Paul Ranson is a consultant who focuses on the regulatory and commercial needs of the pharmaceutical, biotechnology, and medical devices sectors. Paul’s regulatory experience covers both marketing authorization-related matters and market access, pricing, and reimbursement issues. His commercial work is concentrated on transactions with a high degree of industry specificity including collaborations and outsourcing transactions.
Paul spent the early part of his career in in-house roles with Smith Kline, Merck Sharp, and Dohme, and has subsequently maintained this industry focus.
Paul is the legal adviser to the UK trade association for smaller and medium-sized companies (Ethical Medicines Industry Group) and the principal author of the legal module of an MSc on pharmaceutical licensing. He has also been a non-executive director of a specialty pharmaceutical company for some 10 years and was a member of an independent ethics committee for some 5 years.
As a result of his experience, Paul is a frequent speaker at conferences on a variety of topics including licensing, health technology assessment and various regulatory topics including during 2015 the Informa EU Pharmaceutical Law Forum in Europe and BIO and ISPOR in the United States. He has written some 10 reports on pharmaceutical and medical device regulatory issues and has authored/co-authored numerous journal articles.
University of Nottingham, England, 1975, LLB, Law
England & Wales (Solicitor)
Awards and Affiliations
Recommended, Industry Focus: Life Sciences and Healthcare, The Legal 500 UK (2021, 2022)
Recommended, TMT (Technology, Media and Telecoms): Pharmaceuticals and Biotechnology, London, The Legal 500 UK (2019, 2020)
Recognized, London, The Best Lawyers in the United Kingdom (2020)
Ranked, Life Sciences: Regulatory, UK-wide, Chambers UK (2004–2018)
Recognized, Life Sciences: Regulatory, Who's Who Legal (2011–2018)
Recommended, Life Sciences, The Legal 500 (2004–2014)